The first reversible radioligand for the hVMAT2 [3H]reserpine binding site
hVMAT2 [3H]利血平结合位点的第一个可逆放射性配体
基本信息
- 批准号:8451786
- 负责人:
- 金额:$ 25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-01 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAllosteric SiteAmericanAttentionBehavioralBindingBinding SitesBiologicalBiological AssayCarboxylic AcidsCell membraneChemicalsChildChronicCollaborationsCommunitiesCoupledCytoplasmic VesiclesDataDevelopmentDopamineElectronicsElectronsEsterificationEthanolEvaluationFigs - dietaryFoundationsGoalsHealthHumanHuman ActivitiesIn VitroInhibitory Concentration 50KetanserinLabelLaboratoriesLeadLegal patentLettersLigandsLinkMeasuresMedical centerMembrane Transport ProteinsMethamphetamineMethamphetamine dependenceModificationMolecularNational Institute of Drug AbuseNerveNeurotransmittersPharmaceutical PreparationsPharmacologic SubstancePharmacologyPharmacotherapyPhasePopulationPositioning AttributeRadiolabeledReportingResearchReserpineScheduleSerotoninSiteSmall Business Innovation Research GrantSpecific qualifier valueStructureSynapsesSystemTritiumVesicleVeteransanalogdesigndihydrotetrabenazinedopamine transporterinhibitor/antagonistinterestlipophilicitymethamphetamine abuseneurotransmitter uptakenoradrenaline transporternovelpiperidinepresynapticprogramspsychostimulantradioligandradiotracerreceptorserotonin transportersuccesstooluptakevesicular monoamine transportervesicular monoamine transporter 2
项目摘要
DESCRIPTION (provided by applicant): Abuse of methamphetamine (MA) is a major health problem. About 10 million Americans have used MA at least once. Chronic MA use has far reaching health consequences and has a tremendous societal impact. The National Institute on Drug Abuse has expressed considerable interest in the discovery of medications to address this problem. However, currently no medications are available for treatment of MA addiction. MA is a substrate for the Vesicular Monoamine Transporter-2 (VMAT2) located on intracellular storage vesicles in monoaminergic nerve terminals. The goal of this Phase 1 project is to design a potent and selective radioligand that reversibly labels the VMAT2 at a binding site that is coupled to functional activity of the VMAT2. A reversible [3H]ligand linked to functional activity f the VMAT2 will accelerate research toward discovery of medications for MA abuse. The unique ligands proposed here are designed to inhibit VMAT2 uptake by inhibition of the little explored [3H]reserpine binding site on VMAT2. A lead compound in the novel class of arylpiperidinylquinazolines (APQ) has already been demonstrated in our laboratories to bind reversibly at the [3H]reserpine binding site on the VMAT2. Optimization of this compound will now be achieved by sequential molecular modification with respect to binding potency at the VMAT2 and antagonist potency, as measured by inhibition of serotonin and dopamine uptake by the VMAT2. Further molecular modification will be conducted to optimize selectivity against competing binding sites. Topological changes will be introduced to explore the three-dimensional requirements of VMAT2 inhibition. Bioenantioselectivity of the VMAT2 binding site will be exploited by evaluation of enantiopure compounds. Compounds will be modified to optimize electronic, steric and lipophilic factors on functional and inhibitory potency at VMAT2. This project is expected to have a high impact on the search for MA pharmacotherapies as well as on the understanding of the molecular interaction of MA and potential medications that target the VMAT2.
PUBLIC HEALTH RELEVANCE: Methamphetamine abuse, for which there are currently no medications available, has far reaching health consequences and a substantial societal impact. The goal of this project is to design radioligands as molecular tools to explore the interaction of
methamphetamine with its biological target, the Vesicular Monoamine Transporter. These tools will accelerate the search for medications for methamphetamine addiction.
描述(由申请人提供):滥用甲基苯丙胺(MA)是一个主要的健康问题。大约有1000万美国人至少使用过一次MA。长期使用MA具有深远的健康后果,并具有巨大的社会影响。国家药物滥用研究所对发现解决这一问题的药物表示了相当大的兴趣。然而,目前没有药物可用于治疗MA成瘾。MA是位于单胺神经末梢细胞内储存囊泡上的水疱单胺转运蛋白-2 (VMAT2)的底物。这个第一阶段项目的目标是设计一种有效的、选择性的放射性配体,在与VMAT2的功能活性耦合的结合位点可逆地标记VMAT2。与VMAT2功能活性相关的可逆[3H]配体将加速MA滥用药物的研究。本文提出的独特配体旨在通过抑制VMAT2上的[3H]利血平结合位点来抑制VMAT2的摄取。在我们的实验室中,一种新型芳基哌啶基喹唑啉(APQ)的先导化合物已经被证明在VMAT2上的[3H]利血平结合位点可逆结合。该化合物的优化现在将通过对VMAT2的结合效力和拮抗剂效力的顺序分子修饰来实现,通过VMAT2对血清素和多巴胺摄取的抑制来测量。将进行进一步的分子修饰以优化对竞争结合位点的选择性。将引入拓扑变化来探索VMAT2抑制的三维要求。VMAT2结合位点的生物对映体选择性将通过对映纯化合物的评价来开发。将对化合物进行修饰,以优化电子、立体和亲脂因子对VMAT2的功能和抑制效力。该项目预计将对MA药物治疗的研究以及对MA分子相互作用和靶向VMAT2的潜在药物的理解产生重大影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peter C Meltzer其他文献
Peter C Meltzer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peter C Meltzer', 18)}}的其他基金
DISCOVERY OF NOVEL PHARMACOTHERAPIES--COCAINE DEPENDENCE
新型药物疗法的发现——可卡因依赖性
- 批准号:
2466341 - 财政年份:1997
- 资助金额:
$ 25万 - 项目类别:
DISCOVERY OF NOVEL PHARMACOTHERAPIES--COCAINE DEPENDENCE
新型药物疗法的发现——可卡因依赖性
- 批准号:
2898215 - 财政年份:1997
- 资助金额:
$ 25万 - 项目类别:
Discovery of Novel Pharmacotherapies: Cocaine Dependence
新型药物疗法的发现:可卡因依赖性
- 批准号:
6895105 - 财政年份:1997
- 资助金额:
$ 25万 - 项目类别:
Discovery of Novel Pharmacotherapies: Cocaine Dependence
新型药物疗法的发现:可卡因依赖性
- 批准号:
6772140 - 财政年份:1997
- 资助金额:
$ 25万 - 项目类别:
MEDICINAL CHEMISTRY-SYNTHESIS OF POTENTIAL TREATMENT
潜在治疗药物的化学合成
- 批准号:
6082577 - 财政年份:1997
- 资助金额:
$ 25万 - 项目类别:
Discovery of Novel Pharmacotherapies: Cocaine Dependence
新型药物疗法的发现:可卡因依赖性
- 批准号:
7039149 - 财政年份:1997
- 资助金额:
$ 25万 - 项目类别:
DISCOVERY OF NOVEL PHARMACOTHERAPIES--COCAINE DEPENDENCE
新型药物疗法的发现——可卡因依赖性
- 批准号:
2749198 - 财政年份:1997
- 资助金额:
$ 25万 - 项目类别:
MEDICINAL CHEMISTRY-SYNTHESIS OF POTENTIAL TREATMENT
潜在治疗药物的化学合成
- 批准号:
2892671 - 财政年份:1997
- 资助金额:
$ 25万 - 项目类别:
MEDICINAL CHEMISTRY-SYNTHESIS OF POTENTIAL TREATMENT
潜在治疗药物的化学合成
- 批准号:
6344344 - 财政年份:1997
- 资助金额:
$ 25万 - 项目类别:
DISCOVERY OF NOVEL PHARMACOTHERAPIES--COCAINE DEPENDENCE
新型药物疗法的发现——可卡因依赖性
- 批准号:
6378736 - 财政年份:1997
- 资助金额:
$ 25万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Continuing Grant